DOCSLIB.ORG

Laboratory Emerging Pathogens Initiative (Epi) Roll up Modifications Technical and User Manual

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LABORATORY EMERGING PATHOGENS INITIATIVE (EPI) ROLL UP MODIFICATIONS TECHNICAL AND USER MANUAL PATCH LR*5.2*281 Version 5.2 June 2004 Department of Veterans Affairs VistA Health System Design and Development Preface The Veterans Health Information Systems and Architecture (VistA) Laboratory Emerging Pathogens Initiative (EPI) Rollup Modifications Patch LR*5.2*281 Technical and User Manual provides assistance for installing, implementing, and maintaining the EPI software application enhancements. Intended Audience The intended audience for this manual includes the following users and functionalities: • Veterans Health Administration (VHA) facility Information Resource Management (IRM) staff (will be important for installation and implementation of this package) • Laboratory Information Manager (LIM) (will be important for installation and implementation of this package) • Representative from the Microbiology section in support of the Emerging Pathogens Initiative (EPI) Rollup enhancements (i.e., director, supervisor, or technologist) (will be important for installation and implementation of this package especially with parameter and etiology determinations; may also have benefit from local functionality) • Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff or persons at the VHA facility with similar function (will be important for implementation of this package given broad-ranging impact on medical centers and cross-cutting responsibilities that extend beyond traditional service lines; may also have benefit from local functionality) • Infection Control Practitioner (likely to have benefit from local functionality) NOTE: It is highly recommend that the Office of the Director (00) at each VHA facility designate a person or persons who will be responsible for the routine implementation of this patch (both at the time of this installation and afterwards) and to take the lead in trouble-shooting issues that arise with the routine functioning of the process. This decision is left at the discretion of the director since the functions that persons perform locally may have different titles and meanings. The definitions of installation and implementation are provided below to help the Office of the Director in assigning the responsibility. June 2004 VistA Laboratory EPI Rollup Modifications i Technical and User Manual Preface The term installation refers to the process of actually integrating the software into the currently existent VistA system locally. This is usually a process that occurs over a short period of time and does not recur. By default, this process is usually accomplished by personnel in IRM. The term implementation refers to the process of executing the software after installation, adjusting parameters and maintaining the day-to-day functioning of the data cycle that the Laboratory EPI Rollup Modifications entail. There are two main functionalities that will need to be addressed by implementation (national functionality and local functionality). The national functionality will have limited local resource requirements, but will require periodic, on-going attention. Initial parameter set-up will take about 1-2 hours of time with personnel representing the LIM function, microbiology function and IRM function working in concert to set the parameters appropriately. Thereafter, a once-yearly review of the parameter set-up for all national EPI-specified pathogens is the minimum expected. Day-to-day functioning does not refer to the maintenance of the actual software patch, but, instead, refers to the EPI data cycle to assure that the national pathogen information has been appropriately sent to and received by the central data repository—by this definition, it is not necessarily the IRM function to oversee this. Because this will involve review of information sent, confirmation of information receipt, and, most importantly, troubleshooting of errors received from the processing into the central data repository, a local site function that has experience with numerous areas at the local facility from where the data are extracted (medical administrative services, social work, patient demographic information, laboratory information) and that cuts across multiple lines of authority should be considered by the Office of the Director (00) for this task. The local functionality resource requirements will be dependent upon the use at the local site. ii VistA Laboratory EPI Rollup Modifications June 2004 Technical and User Manual Orientation This section of the EPI Roll Up Modifications Technical and User Manual addresses package or audience-specific notations or directions pertaining to symbols used to indicate terminal dialogues and user responses, information for accessing the EPI Technical and User Manual via the Office of Information Field Offices (OIFOs) Anonymous Software directories, VistA website, VistA Documentation Library (VDL), EPI software phased installation and implementation procedures, instructions for seeding EPI historical data, and Austin Automation Center (AAC) transmission schedule for seeding the EPI historical data. EPI Roll Up Modifications Technical and User Manual The EPI Roll Up Modifications Technical and User Manual contains the following sections: Introduction - conveys the major functions, purposes, and how the software accomplishes the objectives. Security Information - addresses any legal requirements pertaining to the EPI Patch LR*5.2*281, software product and identifies any security measures necessary to protect the integrity of the product and database. Pre-Installation Information - contains information that should be acknowledged prior to the installation of Patch LR*5.2*281. Installation Instructions - provides information regarding the installation process for Patch LR*5.2*281. Post Installation Instruction - provides all the necessary information required for the IRM and LIM personnel to implement the Laboratory EPI Rollup Modifications software application. EPI Rollup Modifications User Manual - provides the necessary information for implementing and maintaining the EPI criteria. Appendix A - provides instructions for editing/printing files, using input screens, linking data, and a Workload and Suffixes Codes Request Form. Appendix B - suggest helpful hints and examples regarding for EPI preferred methods, transmissions, and data validation suggestions. Appendix C - provides VistA Health Level Seven (HL7) Protocol tables used to transmit EPI Roll Up Modifications data to the Austin Automation Center (AAC) Appendix D - provides a copy of the IMPLEMENTATION OF LOGICAL OBSERVATION IDENTIFIERS NAMES AND CODES (LOINC®) FOR LABORATORY DATA (VHA Directive 2001- 039) June 2004 VistA Laboratory EPI Rollup Modifications iii Technical and User Manual Orientation Screen Dialogue Screen Captures - The computer dialogue appears in courier font, no larger than 10 points. Example: Courier font 10 points User Response - User entry response appears in boldface type Courier font, no larger than 10 points. Example: Boldface type Return Symbol - User response to computer dialogue is followed by the <Enter> symbol that appears in Courier font, no larger than 10 points, and bolded. Example: <Enter> Tab Symbol - User response to computer dialogue is followed by the symbol that appears in Courier font, no larger than 10 points, and bolded. Example: <Tab> References Please review the following guide and manual prior to installing and implementing the VistA Laboratory EPI Rollup Modifications Patch LR*5.2*281: • Kernel Systems Manual V. 8.0 • VA FileMan V. 21.0 • VA Mailman V. 7.1 EPI Roll Up Modifications Software Phased Installation and Implementation Instructions Due to extensive historical data transmission requirements and mandated setups required for such, a phased installation and implementation of this patch (LR*5.2*281) is utilized for releasing this patch. The software download information is made available to sites attending one of the following national audio conference training calls: Tuesday, June 8 at 1:00 - 3:00 PM EST for VISNs 1-2-3-4-5-6 Thursday, June 10 at 3:00 - 5:00 PM EST for VISNs 7-8-9-10-11 Tuesday, June 15 at 4:00 - 6:00 PM EST for VISNs 12-15-16-16-23 Wednesday, June 16 at 2:00 - 4:00 PM EST for VISNs 18-19-20-21-22 Thursday, June 17 at 2:00 - 4:00 PM EST for those unable to attend the other calls. The VANTS telephone number is 1 800 767-1750 and the access code for all calls is 13143. This patch will involve reseeding of the EPI databases for each site to allow the new data created by this patch to be captured. It is imperative that each site attend an audio conference prior to installation and implementation of the EPI patch LR*5.2*281. iv VistA Laboratory EPI Rollup Modifications June 2004 Technical and User Manual Orientation Instructions for Seeding EPI Historical Data: EPI historical data must be gathered from October 1, 2000 through June 14, 2004. Use the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option to extract and transmit 6 manual runs (consecutive runs) at a time. WARNING: SITES - DO NOT transmit the EPI historical data reports on June 16 or July 4, 2004 to avoid Austin Automation Center (AAC) capacity limitations. Batch #1: October 1, 2000 -March 31, 2001 Batch #2: April 1, 2001 - September 30, 2001 Batch #3: October 1, 2001 - March 31, 2002 Batch #4: April 1, 2002 - September 30, 2002 Batch #5: October 1, 2002 - March 31, 2003 Batch #6: April 1, 2003 - September 30, 2003 Batch #7: October 1, 2003 - March 31, 2004 Batch #8: April
Recommended publications
  • Propoxur United States Environmental Protection Agency

    Propoxur United States Environmental Protection Agency

    United States Prevention, Pesticides EPA738-R-97-009 Environmental Protection And Toxic Substances August 1997 Agency (7508W) Reregistration Eligibility Decision (RED) PROPOXUR UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460 OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES CERTIFIED MAIL Dear Registrant: I am pleased to announce that the Environmental Protection Agency has completed its reregistration eligibility review and decisions on the pesticide chemical case propoxur. The enclosed Reregistration Eligibility Decision (RED) contains the Agency's evaluation of the data base of this chemical, its conclusions of the potential human health and environmental risks of the current product uses, and its decisions and conditions under which these uses and products will be eligible for reregistration. The RED includes the data and labeling requirements for products for reregistration. It may also include requirements for additional data (generic) on the active ingredient to confirm the risk assessments. To assist you with a proper response, read the enclosed document entitled "Summary of Instructions for Responding to the RED." This summary also refers to other enclosed documents which include further instructions. You must follow all instructions and submit complete and timely responses. The first set of required responses is due 90 days from the receipt of this letter. The second set of required responses is due 8 months from the date of receipt of this letter. Complete and timely responses will avoid the Agency taking the enforcement action of suspension against your products. If you have questions on the product specific data requirements or wish to meet with the Agency, please contact the Special Review and Reregistration Division representative Bonnie Adler (703) 308-8523.
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al

    (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al

    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
  • Isoelectric Focussing of Human Thyroxine Binding Globulin (Thyropexin) and Human Prealbumin (Transthyretin)

    Isoelectric Focussing of Human Thyroxine Binding Globulin (Thyropexin) and Human Prealbumin (Transthyretin)

    Luckenbach et al.: Isoelectric focussing of thyropexin and transthyretin 387 Eur. J. Clin. Chem. Clin. Biochem. Vol. 30, 1992, pp. 387-390 © 1992 Walter de Gruyter & Co. Berlin · New York Isoelectric Focussing of Human Thyroxine Binding Globulin (Thyropexin) and Human Prealbumin (Transthyretin) By Christine Luckenbach^ R. Wahl2 and E. Kailee2 1 Institut fur Anthropologie und Humangenetik 2 Medizinische Klinik und Poliklinik, Abteilung IV Eberhard-Karls- Universität Tübingen (Received November 7, 1991/Aprü 22, 1992) Summary: Two batches of the highly purified thyroid hormone-binding plasma proteins, human thyropexin and transthyretin, which were prepared in gram quantities for use in animal experiments, were subjected to analysis by isoelectric focussing. Under these conditions, it was observed that human transthyretin was composed of two components. This was presumably due to the use of 8 mol/1 urea. The preparations of both human transthyretin and human thyropexin contained some products of decomposition which probably arose in the course of the purification processes and, in addition, possibly also contained some normal genetic variants of human thyropexin. In spite of the alterations, both protein preparations largely retained their thyroid hormone-binding capacity, which is essential for in vivo studies on the re-entry of thyroid hormones from the extravascular space into the circulation. For therapeutic use in thyrotoxicosis, human transthyretin seems to be preferable to human thyropexin. Introduction The main thyroid hormone-binding plasma proteins severe thyrotoxicosis in emergencies: The concentra- in humans are thyropexin (1) ("TGB", human thy- tion of both T4 and T3 in the plasma can be signifi- roxine binding inter-alpha globulin (2))1) and trans- cantly enhanced by i.v.
  • Determination of the Residual Efficacy of Carbamate and Organophosphate

    Determination of the Residual Efficacy of Carbamate and Organophosphate

    Yewhalaw et al. Malar J (2017) 16:471 DOI 10.1186/s12936-017-2122-3 Malaria Journal RESEARCH Open Access Determination of the residual efcacy of carbamate and organophosphate insecticides used for indoor residual spraying for malaria control in Ethiopia Delenasaw Yewhalaw1,2†, Meshesha Balkew3†, Josephat Shililu4, Sultan Suleman5, Alemayehu Getachew4, Gedeon Ashenbo4, Sheleme Chibsa6, Gunawardena Dissanayake6, Kristen George7, Dereje Dengela8, Yemane Ye‑Ebiyo4 and Seth R. Irish9* Abstract Background: Indoor residual spraying is one of the key vector control interventions for malaria control in Ethiopia. As malaria transmission is seasonal in most parts of Ethiopia, a single round of spraying can usually provide efective protection against malaria, provided the insecticide remains efective over the entire malaria transmission season. This experiment was designed to evaluate the residual efcacy of bendiocarb, pirimiphos-methyl, and two doses of pro‑ poxur on four diferent wall surfaces (rough mud, smooth mud, dung, and paint). Filter papers afxed to wall surfaces prior to spraying were analyzed to determine the actual concentration applied. Cone bioassays using a susceptible Anopheles arabiensis strain were done monthly to determine the time for which insecticides were efective in killing mosquitoes. Results: The mean insecticide dosage of bendiocarb applied to walls was 486 mg/m2 (target 400/mg). This treat‑ ment lasted 1 month or less on rough mud, smooth mud, and dung, but 4 months on painted surfaces. Pirimiphos- methyl was applied at 1854 mg/m2 (target 1000 mg/m2), and lasted between 4 and 6 months on all wall surfaces. Propoxur with a target dose of 1000 mg/m2 was applied at 320 mg/m2, and lasted 2 months or less on all surfaces, except painted surfaces (4 months).
  • Thomas Addis (1881—1949): Mixing Patients, Rats, and Politics

    Thomas Addis (1881—1949): Mixing Patients, Rats, and Politics

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 37 (1990), pp. 833—840 HISTORICAL ARCHIVE CARL W. GOi-FSCHALK, EDITOR Thomas Addis (1881—1949): Mixing patients, rats, and politics STEVEN J. PEITZMAN Department of Medicine, Division of Nephrology and Hypertension, The Medical College of Pennsylvania, Philadelphia, Pennsylvania, USA In the early decades of the twentieth century, with the threatat the Laboratory of the Royal College of Physicians of Edin- of epidemic infectious diseases already in decline, attentionburgh, one of Great Britain's pioneering medical research shifted to the chronic maladies: hypertension, atherosclerosis,enterprises, also supported by the Carnegie Trusts. obesity, cancer, diabetes—and nephritis, or Bright's disease. Ray Lyman Wilbur (1875—1949), dean of the young Stanford New chemical methods devised by Otto Folin (1867—1934) atMedical School in 1911, "thought it would be a good thing to Harvard and Donald D. Van Slyke (1883—1971) at the Rock-bring in a young scientist from Scotland if the right one could be efeller Institute Hospital empowered the investigation of renalfound who had been trained in German as well as British and metabolic disorders. Folin's colorimetric system provideduniversities, and who was likely to develop in some promising rapid measurement of creatinine, urea, and uric acid, while Vanfield of research" [3]. So Wilbur sent a cable of invitation to Slyke's gasometric analyses allowed quantification of urea andEdinburgh, and the young Scotsman accepted the unlikely total carbon dioxide. Also in the first decades of the twentiethposition: in 1911 Stanford was still a relatively isolated and century, the reform of medical schools provided new opportu-little-known medical school in San Francisco (the school moved nities for academic medical careers.
  • University Microfilms International 300 N

    University Microfilms International 300 N

    INFORMATION TO USERS This was produced from a copy of a document sent to us for microfilming. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the material submitted. The following explanation of techniques is provided to help you understand markings or notations which may appear on this reproduction. 1. The sign or "target” for pages apparently lacking from the document photographed is "Missing Page(s)”. If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting through an image and duplicating adjacent pages to assure you of complete continuity. 2. When an image on the film is obliterated with a round black mark it is an indication that the film inspector noticed either blurred copy because of movement during exposure, or duplicate copy. Unless we meant to delete copyrighted materials that should not have been filmed, you will find a good image of the page in the adjacent frame. If copyrighted materials were deleted you will find a target note listing the pages in the adjacent frame. 3. When a map, drawing or chart, etc., is part of the material being photo­ graphed the photographer has followed a definite method in “sectioning” the material. It is customary to begin filming at the upper left hand corner of a large sheet and to continue from left to right in equal sections with small overlaps. If necessary, sectioning is continued again—beginning below the first row and continuing on until complete.
  • Human Plasma and Recombinant Hemopexins: Heme Binding Revisited

    Human Plasma and Recombinant Hemopexins: Heme Binding Revisited

    International Journal of Molecular Sciences Article Human Plasma and Recombinant Hemopexins: Heme Binding Revisited Elena Karnaukhova 1,*, Catherine Owczarek 2, Peter Schmidt 2, Dominik J. Schaer 3 and Paul W. Buehler 4,5,* 1 Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA 2 CSL Limited, Bio21 Institute, Parkville, Victoria 3010, Australia; [email protected] (C.O.); [email protected] (P.S.) 3 Division of Internal Medicine, University Hospital of Zurich, 8091 Zurich, Switzerland; [email protected] 4 Department of Pathology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA 5 The Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, The University of Maryland School of Medicine, Baltimore, MD 21201, USA * Correspondence: [email protected] (E.K.); [email protected] (P.W.B.) Abstract: Plasma hemopexin (HPX) is the key antioxidant protein of the endogenous clearance pathway that limits the deleterious effects of heme released from hemoglobin and myoglobin (the term “heme” is used in this article to denote both the ferrous and ferric forms). During intra-vascular hemolysis, heme partitioning to protein and lipid increases as the plasma concentration of HPX declines. Therefore, the development of HPX as a replacement therapy during high heme stress could be a relevant intervention for hemolytic disorders. A logical approach to enhance HPX yield involves recombinant production strategies from human cell lines. The present study focuses on a biophysical assessment of heme binding to recombinant human HPX (rhHPX) produced in the Expi293FTM (HEK293) cell system.
  • 2015-02 Toxicology Rapid Testing Panel

    2015-02 Toxicology Rapid Testing Panel

    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
  • An Interactomics Overview of the Human and Bovine Milk Proteome Over Lactation Lina Zhang1, Aalt D

    An Interactomics Overview of the Human and Bovine Milk Proteome Over Lactation Lina Zhang1, Aalt D

    Zhang et al. Proteome Science (2017) 15:1 DOI 10.1186/s12953-016-0110-0 RESEARCH Open Access An interactomics overview of the human and bovine milk proteome over lactation Lina Zhang1, Aalt D. J. van Dijk2,3,4 and Kasper Hettinga1* Abstract Background: Milk is the most important food for growth and development of the neonate, because of its nutrient composition and presence of many bioactive proteins. Differences between human and bovine milk in low abundant proteins have not been extensively studied. To better understand the differences between human and bovine milk, the qualitative and quantitative differences in the milk proteome as well as their changes over lactation were compared using both label-free and labelled proteomics techniques. These datasets were analysed and compared, to better understand the role of milk proteins in development of the newborn. Methods: Human and bovine milk samples were prepared by using filter-aided sample preparation (FASP) combined with dimethyl labelling and analysed by nano LC LTQ-Orbitrap XL mass spectrometry. Results: The human and bovine milk proteome show similarities with regard to the distribution over biological functions, especially the dominant presence of enzymes, transport and immune-related proteins. At a quantitative level, the human and bovine milk proteome differed not only between species but also over lactation within species. Dominant enzymes that differed between species were those assisting in nutrient digestion, with bile salt- activated lipase being abundant in human milk and pancreatic ribonuclease being abundant in bovine milk. As lactation advances, immune-related proteins decreased slower in human milk compared to bovine milk.
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • Simplified Quantitative Methods for Bacteriuria and Pyuria

    Simplified Quantitative Methods for Bacteriuria and Pyuria

    J Clin Pathol: first published as 10.1136/jcp.16.1.32 on 1 January 1963. Downloaded from J. clin. Path. (1963), 16, 32 Simplified quantitative methods for bacteriuria and pyuria JAMES McGEACHIE AND ARTHUR C. KENNEDY From the University Departments of Bacteriology and Medicine, Royal Infirmary, Glasgow SYNOPSIS Although pyelonephritis is a common disease, it escapes clinical detection in an un- desirably high proportion of patients. The present unsatisfactory diagnostic position would be much improved by widespread screening of patients by simple yet reasonably accurate methods. Bacterial counts by the pour-plate technique and estimates of the white cell excretion per hour or day, while undoubtedly of diagnostic value, are probably unsuitable for use on a wide scale. In an attempt to find more convenient procedures a simplified stroke-plate method of bacterial counting and a simplified quantitative white cell count method were devised and applied to over 1,000 mid-stream urine samples from 398 patients. Good correlation was obtained between the simpler stroke-plate method of bacterial counting and the more time-consuming pour-plate method. The quantitative white cell procedure was a much more sensitive index of pyuria than wet-film micro- scopy, and comparison with the bacterial count results showed that it gave a useful indication of urinary infection. It is suggested that a quantitative bacterial count should replace non-quantitativecopyright. culture methods when urinary infection is suspected and that the quantitative white cell count should be performed as a routine part of the initial clinical and laboratory assessment of all patients, followed by a bacterial count if pyuria is revealed.
  • MASSHEALTH TRANSMITTAL LETTER LAB-22 July 2002 TO

    MASSHEALTH TRANSMITTAL LETTER LAB-22 July 2002 TO

    Commonwealth of Massachusetts Executive Office of Health and Human Services Division of Medical Assistance 600 Washington Street Boston, MA 02111 www.mass.gov/dma MASSHEALTH TRANSMITTAL LETTER LAB-22 July 2002 TO: Independent Clinical Laboratories Participating in MassHealth FROM: Wendy E. Warring, Commissioner RE: Independent Clinical Laboratory Manual (Laboratory HCPCS) The federal government has revised the HCFA Common Procedure Coding System (HCPCS) for MassHealth billing. This letter transmits changes for your provider manual that contain the new and revised codes. The revised Subchapter 6 is effective for dates of service on or after April 30, 2002. The codes introduced under the 2002 HCPCS code book are effective for dates of service on or after April 30, 2002. We will accept either the new or the old codes for dates of service through July 28, 2002. For dates of service on or after July 29, 2002, you must use the new codes to receive payment. If you wish to obtain a fee schedule, you may purchase Division of Health Care Finance and Policy regulations from either the Massachusetts State Bookstore or from the Division of Health Care Finance and Policy (see addresses and telephone numbers below). You must contact them first to find out the price of the publication. The Division of Health Care Finance and Policy also has the regulations available on disk. The regulation title for laboratory is 114.3 CMR 20.00: Laboratory. Massachusetts State Bookstore Division of Health Care Finance and Policy State House, Room 116 Two Boylston Street